

Solid Tumor Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/S50E6A74E59MEN.html>

Date: April 2018

Pages: 137

Price: US\$ 3,480.00 (Single User License)

ID: S50E6A74E59MEN

Abstracts

Report Summary

Solid Tumor Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Solid Tumor Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Solid Tumor Drugs 2013-2017, and development forecast 2018-2023

Main market players of Solid Tumor Drugs in EMEA, with company and product introduction, position in the Solid Tumor Drugs market

Market status and development trend of Solid Tumor Drugs by types and applications

Cost and profit status of Solid Tumor Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Solid Tumor Drugs market as:

EMEA Solid Tumor Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Solid Tumor Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Small Molecules

Enzymes
Blood and Blood Components
Gene Therapy
Recombinant Proteins
Somatic Cells
Tissues
Vaccines

EMEA Solid Tumor Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Oncology
Radiology
Neurology
Others

EMEA Solid Tumor Drugs Market: Players Segment Analysis (Company and Product introduction, Solid Tumor Drugs Sales Volume, Revenue, Price and Gross Margin):

AstraZeneca
Abbott Laboratories
Amgen Limited & Amgen Ireland Limited
Biogen
Baxter
Bristol-Myers Squibb Company
F. Hoffmann-La Roche
Eli Lilly and Company
Johnson & Johnson
GlaxoSmithKline
Celgene Corporation
Pfizer

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF SOLID TUMOR DRUGS

- 1.1 Definition of Solid Tumor Drugs in This Report
- 1.2 Commercial Types of Solid Tumor Drugs
 - 1.2.1 Small Molecules
 - 1.2.2 Enzymes
 - 1.2.3 Blood and Blood Components
 - 1.2.4 Gene Therapy
 - 1.2.5 Recombinant Proteins
 - 1.2.6 Somatic Cells
 - 1.2.7 Tissues
 - 1.2.8 Vaccines
- 1.3 Downstream Application of Solid Tumor Drugs
 - 1.3.1 Oncology
 - 1.3.2 Radiology
 - 1.3.3 Neurology
 - 1.3.4 Others
- 1.4 Development History of Solid Tumor Drugs
- 1.5 Market Status and Trend of Solid Tumor Drugs 2013-2023
 - 1.5.1 EMEA Solid Tumor Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Solid Tumor Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Solid Tumor Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Solid Tumor Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Solid Tumor Drugs in EMEA by Regions
 - 2.2.2 Revenue of Solid Tumor Drugs in EMEA by Regions
- 2.3 Market Analysis of Solid Tumor Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Solid Tumor Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Solid Tumor Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Solid Tumor Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Solid Tumor Drugs in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Solid Tumor Drugs in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Solid Tumor Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Solid Tumor Drugs in EMEA by Types
 - 3.1.2 Revenue of Solid Tumor Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Solid Tumor Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Solid Tumor Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Solid Tumor Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Solid Tumor Drugs by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Solid Tumor Drugs by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Solid Tumor Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Solid Tumor Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF SOLID TUMOR DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Solid Tumor Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 SOLID TUMOR DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Solid Tumor Drugs in EMEA by Major Players
- 6.2 Revenue of Solid Tumor Drugs in EMEA by Major Players
- 6.3 Basic Information of Solid Tumor Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Solid Tumor Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Solid Tumor Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 SOLID TUMOR DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AstraZeneca

7.1.1 Company profile

7.1.2 Representative Solid Tumor Drugs Product

7.1.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

7.2 Abbott Laboratories

7.2.1 Company profile

7.2.2 Representative Solid Tumor Drugs Product

7.2.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Abbott

Laboratories

7.3 Amgen Limited & Amgen Ireland Limited

7.3.1 Company profile

7.3.2 Representative Solid Tumor Drugs Product

7.3.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Amgen Limited & Amgen Ireland Limited

7.4 Biogen

7.4.1 Company profile

7.4.2 Representative Solid Tumor Drugs Product

7.4.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Biogen

7.5 Baxter

7.5.1 Company profile

7.5.2 Representative Solid Tumor Drugs Product

7.5.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Baxter

7.6 Bristol-Myers Squibb Company

7.6.1 Company profile

7.6.2 Representative Solid Tumor Drugs Product

7.6.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers

Squibb Company

7.7 F. Hoffmann-La Roche

7.7.1 Company profile

7.7.2 Representative Solid Tumor Drugs Product

7.7.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La

Roche

7.8 Eli Lilly and Company

7.8.1 Company profile

7.8.2 Representative Solid Tumor Drugs Product

7.8.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and

Company

7.9 Johnson & Johnson

7.9.1 Company profile

7.9.2 Representative Solid Tumor Drugs Product

7.9.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.10 GlaxoSmithKline

7.10.1 Company profile

7.10.2 Representative Solid Tumor Drugs Product

7.10.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

7.11 Celgene Corporation

7.11.1 Company profile

7.11.2 Representative Solid Tumor Drugs Product

7.11.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation

7.12 Pfizer

7.12.1 Company profile

7.12.2 Representative Solid Tumor Drugs Product

7.12.3 Solid Tumor Drugs Sales, Revenue, Price and Gross Margin of Pfizer

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF SOLID TUMOR DRUGS

8.1 Industry Chain of Solid Tumor Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF SOLID TUMOR DRUGS

9.1 Cost Structure Analysis of Solid Tumor Drugs

9.2 Raw Materials Cost Analysis of Solid Tumor Drugs

9.3 Labor Cost Analysis of Solid Tumor Drugs

9.4 Manufacturing Expenses Analysis of Solid Tumor Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF SOLID TUMOR DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Solid Tumor Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/S50E6A74E59MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S50E6A74E59MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970